Did a flawed study design affect the results of the VYTAL study?
McMahon
David E
DE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D001384:Azetidines / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011758:Pyrroles / Q000627:therapeutic use*; D011897:Random Allocation; D012107:Research Design; D019821:Simvastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D001384:Azetidines; D004338:Drug Combinations; D000069499:Ezetimibe, Simvastatin Drug Combination; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin